Subject:
- Active Substance: Maribavir
- Name: Livtencity®
- Therapeutic area: Cytomegalovirus (CMV) infection
- Pharmaceutical company: Takeda GmbH
Time table:
- Start: 01.12.2022
- Publication of assessment: 01.03.2023
- End of public hearing: 22.03.2023
- Final decision by G-BA: beginning of 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation